Contrafect Corp (CFRX)

[WolfWayne]

"ContraFect also has several advantages working in its favor. In March 2015, the White House released the National Action Plan for Combating Antibiotic-Resistant Bacteria, where the President laid out 5 goals to developing new antibiotic drugs and specifically pointed to supporting phage-derived lysins to kill specific bacteria. This is significant because it shows government support for an area where ContraFect is currently the only company allowed by the FDA to conduct a phage-derived lysin program. In addition, the FDA granted fast track designation to CF-301, adding another catalyst to the program."